Health Care [ 9/12 ] | Pharmaceuticals [ 57/75 ]
NASDAQ | Common Stock
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea.
The company operates through two segments, Human Health and Animal Health.
It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.
In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea.
The company is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 12, 24 | -1.05 Decreased by -90.91% | -2.37 Increased by +55.70% |
| Aug 13, 24 | -4.04 Decreased by -485.51% | -1.20 Decreased by -236.67% |
| May 14, 24 | -0.07 Increased by +97.07% | -0.03 Decreased by -133.33% |
| Jan 31, 24 | -33.00 Decreased by -862.18% | -73.80 Increased by +55.28% |
| Nov 14, 23 | -0.55 Increased by +93.89% | -1.23 Increased by +55.28% |
| Aug 14, 23 | -0.69 Increased by +92.33% | -1.53 Increased by +54.90% |
| May 15, 23 | -2.39 Increased by +92.04% | -0.04 Decreased by -5.87 K% |
| Mar 27, 23 | -3.43 Increased by +85.25% | -9.75 Increased by +64.82% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 3.11 M Increased by +16.14% | -9.85 M Increased by +18.90% | Decreased by -317.05% Increased by +30.17% |
| Jun 30, 24 | 2.72 M Increased by +37.98% | -9.49 M Increased by +22.21% | Decreased by -348.84% Increased by +43.62% |
| Mar 31, 24 | 2.35 M Decreased by -27.88% | -9.23 M Decreased by -25.01% | Decreased by -392.43% Decreased by -73.35% |
| Sep 30, 23 | 2.81 M Decreased by -10.70% | -7.78 M Increased by +37.88% | Decreased by -276.50% Increased by +30.43% |
| Jun 30, 23 | 2.68 M Decreased by -8.39% | -12.15 M Decreased by -29.71% | Decreased by -454.04% Decreased by -41.59% |
| Mar 31, 23 | 1.97 M Decreased by -24.88% | -12.20 M Increased by +32.16% | Decreased by -618.76% Increased by +9.69% |
| Dec 31, 22 | 3.26 M Increased by +56.73% | -7.38 M Increased by +48.44% | Decreased by -226.38% Increased by +67.10% |
| Sep 30, 22 | 3.15 M Increased by +400.00% | -12.52 M Decreased by -2.69% | Decreased by -397.46% Increased by +79.46% |